Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocannabinoids control spasticity in a multiple sclerosis model.

D Baker1, G Pryce, J L Croxford

  • 1Neuroinflammation Group, Institute of Neurology, University College London, UK.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|February 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.

British journal of pharmacology·2018
Same author

Complex Contact-Based Dynamics of Microsphere Monolayers Revealed by Resonant Attenuation of Surface Acoustic Waves.

Physical review letters·2016
Same author

Laser-induced transient grating setup with continuously tunable period.

The Review of scientific instruments·2016
Same author

In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.

Neurogastroenterology and motility·2015
Same author

Medicinal chemistry of cannabinoids.

Clinical pharmacology and therapeutics·2015
Same author

AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.

British journal of pharmacology·2015

The endocannabinoid system regulates spasticity in multiple sclerosis models. Enhancing natural endocannabinoid levels offers a promising therapeutic strategy with minimal psychotropic effects.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Spasticity is a common and debilitating symptom in multiple sclerosis (MS).
  • A mouse model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) exhibits spasticity similar to MS.
  • Endocannabinoids, such as anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), and palmitoylethanolamide (PEA) are implicated in neurological function.

Purpose of the Study:

  • To investigate the role of the endocannabinoid system in spasticity associated with experimental autoimmune encephalomyelitis.
  • To explore the therapeutic potential of modulating endocannabinoid levels for spasticity management.

Main Methods:

  • Analysis of endocannabinoid and related lipid levels in brain tissue from spastic and non-spastic CREAE mice.

Related Experiment Videos

  • Administration of exogenous endocannabinoids and PEA to assess their effect on spasticity.
  • Treatment with selective inhibitors of endocannabinoid re-uptake and hydrolysis to evaluate spasticity amelioration.

    • Main Results:

    • Increased levels of anandamide (AEA), 2-arachidonoyl glycerol (2-AG), and palmitoylethanolamide (PEA) were found in nerve-damaged areas of spastic CREAE mice.
    • Exogenous administration of AEA, 2-AG, and PEA reduced spasticity.
    • Inhibitors targeting endocannabinoid metabolism significantly ameliorated spasticity, comparable to cannabinoid receptor agonists.

    Conclusions:

    • The endocannabinoid system tonically controls spasticity in this MS model.
    • Modulating endogenous endocannabinoid levels represents a novel therapeutic avenue for multiple sclerosis and other neuromuscular disorders.
    • These agents may offer spasticity relief with reduced psychotropic side effects.